Ascentage Pharma Outlined its Global Innovation Strategy During Presentation at 44th Annual J.P. Morgan Healthcare Conference
Ascentage Pharma Group International (NASDAQ:AAPG) is now covered by analysts at Rodman & Renshaw. They set a "buy" rating and a $48.00 price target on the stock.
Ascentage Pharma Announces IND Clearance by the U.S. Food and Drug Administration for BTK Degrader APG-3288
Ascentage Pharma Group International (NASDAQ:AAPG) was upgraded by analysts at Lucid Cap Mkts to a "strong-buy" rating.
Ascentage Pharma to Present at 44th Annual J.P. Morgan Healthcare Conference